AbbVie Breaks Ground on North Chicago Manufacturing Facility - Chicago ...

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicinesFacility expected to be fully operational and serving patients by 2027Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing

AbbVie breaks ground on North Chicago manufacturing facility - Chicago ...

Pharma Pulse: Measles Vaccination Gaps Persist, FDA Approves Guselkumab for Children, and AbbVie Expands US Manufacturing

This episode of Pharma Pulse covers new data showing measles vaccine coverage remains below herd immunity thresholds, the FDA’s approval of guselkumab for pediatric plaque psoriasis and psoriatic arthritis, and AbbVie breaking ground on a new API manufacturing site in Illinois.

AbbVie breaks ground on new API facility in North Chicago

NORTH CHICAGO, Ill. — AbbVie has begun construction of a new active pharmaceutical ingredient (API) manufacturing plant at its headquarters campus in North Chicago, marking a major milestone in the company’s U.S. manufacturing expansion.The state-of-the-art facility, announced on September 29, will focus on the production of medicines for immunology, oncology, and neuroscience. AbbVie stated that the site is expected to be fully operational by 2…

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility - Life Sciences British Columbia

NORTH CHICAGO, Ill. - AbbVie announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant.